Affiliation:
1. College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar
2. Sidra Medical and Research Center, Ar-Rayyan P.O. Box 26999, Qatar
Abstract
Gliomas, which arise from glial cells in the brain, remain a significant challenge due to their location and resistance to traditional treatments. Despite research efforts and advancements in healthcare, the incidence of gliomas has risen dramatically over the past two decades. The dysregulation of microRNAs (miRNAs) has prompted the creation of therapeutic agents that specially target them. However, it has been reported that they are involved in complex signaling pathways that contribute to the loss of expression of tumor suppressor genes and the upregulation of the expression of oncogenes. In addition, numerous miRNAs promote the development, progression, and recurrence of gliomas by targeting crucial proteins and enzymes involved in metabolic pathways such as glycolysis and oxidative phosphorylation. However, the complex interplay among these pathways along with other obstacles hinders the ability to apply miRNA targeting in clinical practice. This highlights the importance of identifying specific miRNAs to be targeted for therapy and having a complete understanding of the diverse pathways they are involved in. Therefore, the aim of this review is to provide an overview of the role of miRNAs in the progression and prognosis of gliomas, emphasizing the different pathways involved and identifying potential therapeutic targets.
Funder
Qatar National Research Fund
Reference64 articles.
1. Gousias, K., Theocharous, T., and Simon, M. (2022). Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma. Biomedicines, 10.
2. Epidemiology and Overview of Gliomas;Davis;Semin. Oncol. Nurs.,2018
3. Burden and trends of brain and central nervous system cancer from 1990 to 2019 at the global, regional, and country levels;Fan;Arch. Public Health,2022
4. Epidemiology of Brain and Other Central Nervous System Cancers in the North Africa and Middle East Region: A Systematic Analysis of the Global Burden of Disease Study 1990–2019;Mohammadi;World Neurosurg.,2023
5. IDH1 and IDH2 Mutations in Gliomas;Yan;N. Engl. J. Med.,2009